Literature DB >> 10537352

Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study.

M Baekelandt1, R Holm, C G Tropé, J M Nesland, G B Kristensen.   

Abstract

The eukaryotic cell cycle is controlled by protein complexes consisting of cyclin-dependent kinases and cyclins. The cyclin-dependent kinases are in turn negatively regulated by a family of cyclin-dependent kinase inhibitors, comprising, among others, the p21 and p27 proteins. p21 and p27 have been shown to be of prognostic significance in a broad array of human tumors. Using immunohistochemistry, the frequency of expression and the possible prognostic and predictive significance of these proteins were examined in a series of 185 uniformly treated patients with stage III ovarian cancer. We found p21 to be overexpressed in 48% of cases. No significant correlation was found between the expression of p21 and p53 proteins (P = 0.273). A low level of p27 was demonstrated in 48.5% of cases. p21 overexpression correlated with lower Fédération Internationale des Gynaecologistes et Obstetristes substage, lower patient age, and absence of ascites, but neither p21 nor p27 expression was of prognostic significance for the whole group of patients. Only a trend toward reduced survival (P = 0.092) was noticed for the small subgroup of patients (6%), whose tumors lacked p27 expression completely. A clear positive correlation could be found between p21 and p27 protein expression (P = 0.012). Despite the suggested role of the 21 and p27 proteins in determining drug sensitivity, they were not found to be predictive for response to chemotherapy, as assessed by second-look laparotomy in this large group of patients with advanced ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537352

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer.

Authors:  Annette Schmider-Ross; Olaf Pirsig; Elisabeth Gottschalk; Carsten Denkert; Werner Lichtenegger; Angela Reles
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-19       Impact factor: 4.553

Review 2.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

3.  Expression of p27 and p16 and their clinical significance in gastric cancer.

Authors:  S Kumari; P Kumar; M Kumar; S Singh; G Narayan
Journal:  Clin Transl Oncol       Date:  2020-09-02       Impact factor: 3.405

4.  MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.

Authors:  Kaitlyn Wurz; Rochelle L Garcia; Barbara A Goff; Patrick S Mitchell; Jun Haeng Lee; Muneesh Tewari; Elizabeth M Swisher
Journal:  Genes Chromosomes Cancer       Date:  2010-07       Impact factor: 5.006

5.  Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway.

Authors:  Rui Hou; Luo Jiang; Zhuo Yang; Shizhuo Wang; Qifang Liu
Journal:  Tumour Biol       Date:  2016-10-07

6.  Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck.

Authors:  Dapeng Lei; Erich M Sturgis; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

Review 7.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

8.  Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.

Authors:  M Schuyer; M E van der Burg; S C Henzen-Logmans; J H Fieret; J G Klijn; M P Look; J A Foekens; G Stoter; E M Berns
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.